Document is current

Documents that mention this clinical trial

Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial
https://doi.org/10.2337/dc21-1429

The Cross-sectional and Longitudinal Associations of Diabetic Retinopathy With Cognitive Function and Brain MRI Findings: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
https://doi.org/10.2337/dc14-0502

Interplay between worsening kidney function and cardiovascular events in patients with type 2 diabetes: an analysis from the ACCORD trial
https://doi.org/10.1136/bmjdrc-2021-002408

Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial
https://doi.org/10.1016/s0140-6736(14)60611-5

Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus
https://doi.org/10.1186/s12933-021-01393-5

Impact of Intensive Glycemic Control on the Incidence of Atrial Fibrillation and Associated Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study)
https://doi.org/10.1016/j.amjcard.2014.07.045

Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
https://doi.org/10.1016/j.ahj.2009.09.017

<i>PPARA</i> Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid
https://doi.org/10.2337/db19-0973

A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment
https://doi.org/10.2337/dc20-2700

Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial
https://doi.org/10.2337/dc18-0709

Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes
https://doi.org/10.2337/dc15-2283

Visual acuity outcomes after cataract surgery in type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study
https://doi.org/10.1136/bjophthalmol-2020-317793

Effect of Intensive Glycemic and Blood Pressure Control on QT Prolongation in Diabetes: The ACCORD Trial ^(Results)
https://doi.org/10.2337/db20-0401

Trimethylamine N-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis
https://doi.org/10.1136/bmjdrc-2019-000718

Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes
https://doi.org/10.2337/dc17-1740

The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes
https://doi.org/10.1016/j.ophtha.2014.07.019

Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score
https://doi.org/10.2337/dc19-0587

Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial ^(Results)
https://doi.org/10.2337/dc20-1842

Changes in fat mass and lean body mass and outcomes in type 2 diabetes mellitus
https://doi.org/10.1007/s11739-021-02916-4

Protocol for a preclinical systematic review and meta-analysis of pharmacological targeting of peroxisome proliferator-activated receptors in experimental renal injury
https://doi.org/10.1136/bmjos-2021-100240

Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study
https://doi.org/10.1186/s12933-020-01002-x

Intensive versus standard blood pressure control in type 2 diabetes: a restricted mean survival time analysis of a randomised controlled trial ^{(Post-results)}
https://doi.org/10.1136/bmjopen-2021-050335

Association of the cumulative triglyceride-glucose index with major adverse cardiovascular events in patients with type 2 diabetes
https://doi.org/10.1186/s12933-022-01599-1

Genetic Variants in <i>CPA6</i> and <i>PRPF31</i> Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes
https://doi.org/10.2337/db17-1164

Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes
https://doi.org/10.2215/cjn.06200518

The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial
https://doi.org/10.2337/dc14-1844

Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial
https://doi.org/10.2337/dc16-0285

Waist circumference is associated with major adverse cardiovascular events in male but not female patients with type-2 diabetes mellitus
https://doi.org/10.1186/s12933-020-01007-6

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
https://doi.org/10.1016/s0140-6736(10)60576-4

Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD
https://doi.org/10.2337/dc17-1638